MGI, a company committed to building core tools and technology to lead life science, today announced its collaboration with Prepaire Labs at MEDLAB Middle East 2024 to further empower precision medicine.

The collaboration, includes MGI’s first corporate order of the revolutionary DNBSEQ-T20×2 (“T20”) ultra-high throughput sequencer in the Middle East and the first application of the company’s sequencing technology in drug discovery in the region.

“We are thrilled to work with Prepaire Labs to harness T20’s ultra-high throughput and great cost-efficiency for understanding and treating diseases at a personalized level,” said Roy Tan, General Manager of MGI Asia Pacific. “This partnership is a testament to our commitment to expand global access to genomics through cutting-edge and high-quality platforms.”

Powered by MGI’s proprietary DNBSEQTM technology, T20 is a fully automated genetic sequencer that has achieved major technological breakthroughs and made waves in the global industry for lowering genome sequencing cost to sub-$100 per genome.

Designed to meet the most challenging sequencing scenarios, it covers all high-throughput sequencing needs in scientific research and clinical applications, including WGS, WGBS, stLFR, single-cell sequencing, Stereo-seq and more.

MGI and Prepaire Labs will focus on developing assays for whole genome sequencing, creating a 100% automated smart laboratory, innovating sequencing methods for complex genome analysis and co-marketing to enhance scientific collaboration.

Founded in 2020, Prepaire Labs is an Abu Dhabi-based company focused on revolutionizing drug discovery and precision medicine. With an initiative to establish an advanced semi-autonomous BSL3 Laboratory in the UAE, the addition of T20 will equip Prepaire Labs with the capacity to provide adaptable genome sequencing services, vital to the Biotune platform’s cost-effective and tailored healthcare solutions.

Carl Freer, founder of Prepaire Labs, commented, “Our collaboration with MGI is a testament to our mission of bringing advanced genomic sequencing closer to clinical applications. Together, we are building on our recent advancements to further empower researchers and healthcare providers.”

MGI’s DNBSEQ-T20×2, along with other products including the state-of-the-art ZOID-ILR Laboratory Robot, DNBSEQTM platforms, automated sample preparation systems, and ultra-low-temperature biorepository solutions, will be on exhibit at MEDLAB Middle East 2024. Attendees are welcome to visit MGI’s booth #Z4.H10 in Dubai World Trade Centre between 5 and 8 February.